StockDuty ← Dashboard Aug 31, 2026 09:11 PM ET
SignalCorporate

Innocan Pharma Announces Second Quarter Fiscal year 2026 Results, With Revenue of US$5.25M (CAD 7.3M)

Revenue beat expectations with US$5.25M reported, signaling strong corporate performance.

What changed
Why it matters
Revenue beat expectations with US$5.25M reported, signaling strong corporate performance.
Sources
eodhd
Related signals
FITCH AFFIRMS CHINA CREDIT RATING AT 'A' →FITCH ISSUES NEW STATEMENT AND OUTLOOK ON U.S . CREDIT RATING DEBT WARNING IN FIRST PARAGRAPH . →SCOTT BESSENT SURPRISE BOND BUYBACK SPARKS A SILVER RALLY . IS IT TOO LATE TO BUY IN ? →